Advertisement

Advances in Therapy

, Volume 20, Issue 3, pp 129–137 | Cite as

Managing childhood atopic dermatitis

  • Alexander K. C. Leung
  • Kirk A. Barber
Article

Abstract

Atopic dermatitis, a chronic inflammatory skin disorder that affects up to 20% of school-aged children, can profoundly influence quality of life. Basic therapy consists of avoidance of triggering factors and optimal skin care. Until now, corticosteroids have been the usual treatment for acute flares. Short-term safety profiles are reasonable, but long-term use of corticosteroids may involve significant adverse effects. Topical immunomodulators (tacrolimus and pimecrolimus) are beneficial and safe for adults and children and represent a major new alternative to chronic cortico-steroid use, especially in children.

Keywords

atopic dermatitis children immunomodulator tacrolimus pimecrolimus 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Leung AK, Martin S Drug therapy for some common pediatric skin eruptions.Drug Protocol. 1987;2:9–20.Google Scholar
  2. 2.
    Eichenfield LF, Lucky AW, Boguniewicz M, et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents.JAm Acad Dermatol. 2002;46:491–504.Google Scholar
  3. 3.
    Drake L, Prendergast M, Maher R, et al. The impact of tacrolimus ointment on health-related quality of life of adults and pediatric patients with atopic dermatitis.J Am Acad Dermatol. 2001; 44:S65-S72.PubMedCrossRefGoogle Scholar
  4. 4.
    Kiebert G, Sorensen SV, Revicki D, et al. Atopic dermatitis is associated with a decrement in health-related quality of life.Int J Dermatol. 2002;41:151–158.PubMedCrossRefGoogle Scholar
  5. 5.
    DiCarlo JB, McCall CO Pharmacologic alternatives for severe atopic dermatitis.Int J Dermatol. 2001;40:82–88.PubMedCrossRefGoogle Scholar
  6. 6.
    Schultz Larsen E. Atopic dermatitis: a genetic epidemiologic study in a population based twin sample.J Am Acad Dermatol. 1993;28:719–723.Google Scholar
  7. 7.
    Knoell KA, Greer KE. Atopic dermatitis.Pediatr Rev. 1999;20:46–51.PubMedCrossRefGoogle Scholar
  8. 8.
    Williams HC, Burney PG, Pembroke AC, et al. The U.K. Working Party’s diagnostic criteria for atopic dermatitis, III: independent hospital validation.Br J Dermatol. 1994;131:406–416.PubMedCrossRefGoogle Scholar
  9. 9.
    Fleischer AB Jr. Treatment of atopic dermatitis: role of tacrolimus ointment as a topical noncorti-costeroid therapy.J Allergy Clin Immunol. 1999;104:S126-S130.PubMedCrossRefGoogle Scholar
  10. 10.
    Rudikoff D, Lebwohl M. Atopic dermatitis.Lancet. 1998;351:1715–1721.PubMedCrossRefGoogle Scholar
  11. 11.
    Kristal L, Klein PA. Atopic dermatitis in infants and children.Pediatr Clin North Am. 2000;47: 877–895.PubMedCrossRefGoogle Scholar
  12. 12.
    Eigenmann PA. Clinical features and diagnostic criteria of atopic dermatitis in relation to age.Pediatr Allergy Immunol. 2001;12(suppl 14):69–74.PubMedCrossRefGoogle Scholar
  13. 13.
    Leung DY, Tharp M, Boguniewicz M Atopic dermatitis (atopic eczema). In: Freedberg IM, Eisen AZ, Wolft K, et al. eds.Fitzpatrick’s Dermatology in General Medicine. New York: McGraw-Hill; 1999:1464–1480.Google Scholar
  14. 14.
    Whalley D, Huels J, McKenna SP. The benefit of pimecrolimus (Elidel, SDZ ASM 981) on parents’ quality of life in the treatment of pediatric atopic dermatitis.Pediatrics. 2002;110:1133–1136.PubMedCrossRefGoogle Scholar
  15. 15.
    Hogan PA. Atopic dermatitis: what to do when the itch becomes too much.Med J Aust. 1996; 164:736–741.PubMedGoogle Scholar
  16. 16.
    Rothe MJ, Grant-Kels JM. Atopic dermatitis: an update.J Am Acad Dermatol. 1996;35:1–13.PubMedCrossRefGoogle Scholar
  17. 17.
    Gontzes P, Bahna SL. Food allergy for the primary care physician.Prim Care. 1987;14:547–558.PubMedGoogle Scholar
  18. 18.
    Sampson HA. The immunopathogenic role of food hypersensitivity in atopic dermatitis.Acta Derm Venereol. 1992;176:S34-S37.Google Scholar
  19. 19.
    Leung AK. Food allergy: a clinical approach.Adv Pediatr. 1998;45:145–177.PubMedGoogle Scholar
  20. 20.
    Kemp AS. Food allergy in children.Aust Fam Physician. 1993;22:1959–1963.PubMedGoogle Scholar
  21. 21.
    Raimer SS. Managing pediatric atopic dermatitis.Clin Pediatr. 2000;39:1–14.CrossRefGoogle Scholar
  22. 22.
    Hanifin JM. Atopic dermatitis in infants and children.Pediatr Clin North Am. 1991;38:763–789.PubMedGoogle Scholar
  23. 23.
    Sampson HA, McCaskill CC. Food hypersensitivity and atopic dermatitis: evaluation of 113 patients.J Pediatr. 1985;107:669–675.PubMedCrossRefGoogle Scholar
  24. 24.
    Lewis-Jones S. Atopic dermatitis in childhood.Hosp Med. 2001;62:136–143.PubMedGoogle Scholar
  25. 25.
    Vandenplas Y. The use of hydrolysates in allergy prevention programmes.Eur J Clin Nutr. 1995;49:S84-S91.PubMedGoogle Scholar
  26. 26.
    Leung AK, Bowen TJ. Seasonal allergic rhinitis and food allergy. In: Bergman AB, ed.Twenty Common Problems in Pediatrics. New York: McGraw-Hill; 2001:219–233.Google Scholar
  27. 27.
    Correale C, Walker C, Murphy L, et al. Atopic dermatitis: a review of diagnosis and treatment.Am Fam Physician. 1999;60:1191–1198.PubMedGoogle Scholar
  28. 28.
    Lucky AW, Leach AD, Laskarzewski P, et al. Use of an emollient as a steroid-sparing agent in the treatment of mild to moderate atopic dermatitis in children.Pediatr Dermatol. 1997;14: 321–324.PubMedGoogle Scholar
  29. 29.
    Denman ST. A review of pruritus.J Am Acad Dermatol. 1986;14:375–392.PubMedCrossRefGoogle Scholar
  30. 30.
    Leung AK, Wong BE, Chan PY, et al. Pruritus in children.J R Soc Health. 1998;118:280–286.PubMedCrossRefGoogle Scholar
  31. 31.
    Pustisek N, Lipozencic J, Ljubojevics S. Tacrolimus ointment: a new therapy for atopic dermatitis—review of the literature.Acta Dermatovenerol Croat. 2002;10:25–32.PubMedGoogle Scholar
  32. 32.
    Woodmansee D, Christiansen S. Atopic dermatitis.Pediatr Ann. 1998;27:710–716.PubMedGoogle Scholar
  33. 33.
    Ruiz-Maldonado R, Zapata G, Tamayo L., et al. Cushing’s syndrome after topical application of corticosteroids.Am J Dis Child. 1982;136:274–275.PubMedGoogle Scholar
  34. 34.
    Stoppoloni G, Prisco F, Santinelli R., et al. Potential hazards of topical steroid therapy.Am J Dis Child. 1983;137:1130–1131.PubMedGoogle Scholar
  35. 35.
    Allen BR. Tacrolimus ointment: its place in the therapy of atopic dermatitis.J Allergy Clin Immunol. 2002;109:401–403.PubMedCrossRefGoogle Scholar
  36. 36.
    Bernard LA, Eichenfield LF. Topical immunomodulators for atopic dermatitis.Curr Opin Pediatr. 2002;14:414–418.PubMedCrossRefGoogle Scholar
  37. 37.
    Kim HJ, Honig PJ. Atopic dermatitis.Curr Opin Pediatr. 1998;10:387–392.PubMedCrossRefGoogle Scholar
  38. 38.
    Boguniewicz M, Fiedler VC, Raimer S., et al. A randomized, vehicle-controlled trial of tacrolimus ointment for the treatment of atopic dermatitis in children.J Allergy Clin Immunol. 1998;102: 637–644.PubMedCrossRefGoogle Scholar
  39. 39.
    Hanifin J, Ling M, Langley R, et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients, part I: efficacy.J Am Acad Dermatol. 2001;44(suppl):S28-S38.PubMedCrossRefGoogle Scholar
  40. 40.
    Kang S, Lucky AW, Pariser D, et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children.J Am Acad Dermatol. 2001;44:S58-S64.PubMedCrossRefGoogle Scholar
  41. 41.
    Paller A, Eichenfield L, Leung D, et al. A12 week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients.J Am Acad Dermatol. 2001;44:S47-S57.PubMedCrossRefGoogle Scholar
  42. 42.
    Ruzicka T, Bieber T, Schöpf E, et al. A short-term trial of tacrolimus ointment for atopic dermatitis.N Engl J Med. 1997;337:816–821.PubMedCrossRefGoogle Scholar
  43. 43.
    Soter N, Fleischer AB Jr, Webster G, et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients, part II: safety.J Am Acad Dermatol. 2001;44(suppl):S39-S46.PubMedCrossRefGoogle Scholar
  44. 44.
    Reitamo S, Rustin M, Ruzicka T, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis.J Allergy Clin Immunol. 2002;109:547–555.PubMedCrossRefGoogle Scholar
  45. 45.
    Reitamo S, Van Leent EJ, Ho V, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis.J Allergy Clin Immunol. 2002;109:539–546.PubMedCrossRefGoogle Scholar
  46. 46.
    Bekersky I, Fitzsimmons W, Tanase A, et al. Nonclinical and early clinical development of tacrolimus ointment for the treatment of atopic dermatitis.J Am Acad Dermatol. 2001;44:S17-S27.PubMedCrossRefGoogle Scholar
  47. 47.
    Reitamo S, Rissanen J, Remitz A, et al. Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial.J Invest Dermatol. 1998;111:396–398.PubMedCrossRefGoogle Scholar
  48. 48.
    Fleischer AB Jr, Ling M, Eichenfield L, et al. Tacrolimus ointment for the treatment of atopic dermatitis is not associated with an increase in cutaneous infections.J Am Acad Dermatol. 2002; 47:562–570.PubMedCrossRefGoogle Scholar
  49. 49.
    Reitamo S, Wollenberg A, Schöpf E, et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis.Arch Dermatol. 2000;136:999–1006.PubMedCrossRefGoogle Scholar
  50. 50.
    Paller A, Hanifin J, Eichenfield L, et al. Long-term safety of topically applied tacrolimus ointment in pediatric patients 2–15 years of age with atopic dermatitis.J Eur Acad Dermatol Venereol. 2002; 16(suppl 1):136. Abstract.Google Scholar
  51. 51.
    Luger T, van Leent EJ, Graeber M, et al. SDZ AZM 981: an emerging safe and effective treatment for atopic dermatitis.Br J Dermatol. 2001;144:788–794.PubMedCrossRefGoogle Scholar
  52. 52.
    Van Leent FJ, Gräber M, Thurston M, et al. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis.Arch Dermatol. 1998;134:805–809.PubMedCrossRefGoogle Scholar
  53. 53.
    Wellington K, Jarvis B. Topical pimecrolimus: a review of its clinical potential in the management of atopic dermatitis.Drugs. 2002;62:817–840.PubMedCrossRefGoogle Scholar
  54. 54.
    Wahn U, Bos JD, Goodfield M, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children.Pediatrics. 2002;110:e2.PubMedCrossRefGoogle Scholar
  55. 55.
    Harper J, Green A, Scott G, et al. First experience of topical SDZ ASM 981 in children with atopic dermatitis.Br J Dermatol. 2001;144:781–787.PubMedCrossRefGoogle Scholar
  56. 56.
    Reitamo S, Remitz A, Kyllonen H, et al. Topical noncorticosteroid immunomodulation in the treatment of atopic dermatitis.Am J Clin Dermatol. 2002;3:381–388.PubMedCrossRefGoogle Scholar
  57. 57.
    Naylor MF, Elmets CA, Satoi MS, et al. Treatment with tacrolimus ointment is not associated with an increase in non-melanoma skin cancer.J Eur Acad Dermatol Venereol. 2002;16(suppl 1): 138. Abstract.Google Scholar
  58. 58.
    Cheer SM, Plosker GL. Tacrolimus ointment: a review of its therapeutic potential as a topical therapy in atopic dermatitis.Am J Clin Dermatol. 2001;2:389–406.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science and Business Media and LLC 2003

Authors and Affiliations

  • Alexander K. C. Leung
    • 1
  • Kirk A. Barber
    • 2
  1. 1.Department of PediatricsUniversity of CalgaryCanada
  2. 2.Departments of Internal Medicine and Community Health SciencesUniversity of CalgaryCalgaryCanada

Personalised recommendations